期刊文献+

更昔洛韦对肾小管上皮细胞生长和能量代谢的影响

Effects of gancrclovior on growth and energy metabolism of renal epithelial cell
下载PDF
导出
摘要 目的:观察更昔洛韦对人肾小管上皮细胞生长及能量代谢的影响。方法:分别以3种不同浓度的更昔洛韦(1μg.ml-1,10μg.ml-1,100μg.ml-1)作用人肾小管上皮细胞HKCs细胞,应用MTT比色法作生长曲线,观察更昔洛韦对肾小管上皮细胞增殖的影响。同时,应用反相高效液相色谱法检测不同浓度药物作用24 h和48 h时各组细胞内ATP含量的变化。结果:实验组与对照组比较,不同浓度更昔洛韦对肾小管上皮细胞生长无明显影响(P>0.05)。药物浓度为100μg.ml-1实验组作用48 h后,细胞ATP含量比对照组低(P<0.05),其余与对照组无显著差异(P>0.05)。结论:更昔洛韦在治疗浓度范围内,对肾小管上皮细胞生长及能量代谢无明显影响,只有达较高浓度时对细胞能量代谢才有抑制作用,可能是临床上引起肾功改变的原因之一。 Objective:To study the effects of gancrclovior(GCV) on growth and energy metabolism of renal epithelial cell, Methods: HKC strain were treated with three concentrations of GCV(lpg/ml, 10μg/ml and 100μg/ml) for 24 h and 48 h, respectively, and then the proliferation of HKC strain were detected with MTT method. The concentration of ATP in HKC strain of three treated groups was measured by high performance liquid chromatography, Results:Compared with that of the control group, the growth of HKC strain was affected by GCV at different concentrations(P〉0. 05), The concentration of ATP in HKC strain of the group treated with 100μg/ml GCV for 48 h was lower than that of the control group(P〈0. 05) and the concentration of ATP of other two treated groups was similar to that of the control group(P〉0. 05). Conclusion:GCV has not significant effects on the growth and energy metabolism of renal epithelial cell among its therapeutic dosage range. Only when its dosage is very high, it inhibits the energy metabolism of the renal epithelial cell, which may be one of causes inducing changes of renal function.
机构地区 解放军第
出处 《西南国防医药》 CAS 2006年第5期491-492,共2页 Medical Journal of National Defending Forces in Southwest China
关键词 更昔洛韦 肾小管上皮细胞 HKCs细胞株 ATP MTT法 gancrclovir, renal epithelial cell, HKC strain, proliferation, energy metabolism
  • 相关文献

参考文献3

二级参考文献19

  • 1Schnitzler MA, Lowell JA, Hardinger KL, et al. The association of cytomegalovirus sero-pairing with outcomes and costs following cadaveric renal transplantation prior to the introduction of oral ganciclovir CMV prophylaxis. Am J Transplant, 2003, 3: 445-451.
  • 2Geddes CC, Church CC, Collidge T, et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant, 2003, 18: 1891-1898.
  • 3Rubin RH, Ikonen T, Gummet JF, et al. The therapeutic of the organ transplant recipient: the linkage of Immunosuppression and antimicrobial strategies. Transpt Infect Dis, 1999, 1: 29.
  • 4Couchoud C, Cucherat M, Haugh M, et al. Cytomegalovirus prophylaxis with antiviral agents is solid organ transplantation.Transplantation, 1998, 65: 641-647.
  • 5Vilacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpt Infect Dis, 1999, 1: 50.
  • 6Schnitzler MA. Costs and consequences of cytomegalovirus disease. Am J Health Syst Pharm, 2003, 60: 5-8.
  • 7Murray BM, Subramaniam S. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.Transpl Infect Dis, 2004, 6: 3-9.
  • 8Sagedal S, Nordal XP, Hartmann A. Pre-emptive therpy of CMVpp65 antigen positiverenal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant, 2003, 18: 1899-1908.
  • 9Dickenmann MJ, Kabulbayev K, Steiger J, et al. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Clin Microbiol Infect, 2004, 10: 337-339.
  • 10Melgosa Hijosa M, Garcia Meseguer C, Pena Garcia P, et al.Preemptive treatment with oral ganciclovir for pediatric renal transplantation. Clin Nephrol, 2004, 61: 246-252.

共引文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部